INCYTE CORP (INCY) Stock News
NASDAQ:INCY - Nasdaq - US45337C1027 - Common Stock - Currency: USD
INCY Latest News, Press Relases and Analysis
Top S&P500 movers in Friday's session
Curious about the S&P500 stocks that are in motion on Friday? Join us as we explore the top movers within the S&P500 index during today's session.
Uncover the latest developments among S&P500 stocks in today's session.
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Thursday. Uncover the top gainers and losers in today's session for valuable insights.
Jim Cramer Highlights That Incyte’s New CEO is an “Industry Veteran”
Incyte Corporation (NASDAQ:INCY) is one of the top 10 S&P 500 winners of the day that Jim Cramer highlighted. Cramer appreciated the new CEO of the company, as he commented: “We then have Incyte. That’s a biotech company. It just got a new CEO, Bill Meury. He’s an industry veteran, known as a deal maker. […]
Shell denies deal talks with BP, Micron reports Q3 beat: Morning Buzz
The major averages were higher near noon, with the S&P 500 continuing its path towards all-time highs reached earlier this year. Meanwhile, the U.S. dollar is under pressure amid the worst first-half performance in 50 years, falling to its lowest since early 2022 amid speculation that President Trump may replace Fed Chair Powell before his term ends and markets pricing in over 60 basis points of rate cuts by year-end. Looking to commodities, the price of gold was fractionally lower, continuing a
Incyte CEO Shake-Up Sparks M&A Buzz As RBC Analyst Highlights Meury’s Track Record: Retail Is All In
Bill Meury previously led Karuna Therapeutics through a $14 billion sale to Bristol Myers Squibb and steered Anthos Therapeutics ahead of its acquisition by Novartis.
Thursday's session: top gainers and losers in the S&P500 index
Curious about the top performers within the S&P500 index in the middle of the day on Thursday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Why New Incyte CEO Bill Meury Is Stoking Investors' M&A Hopes
Bill Meury will take the place of Herve Hoppenot, who is retiring after 11 years at Incyte's helm.
Get insights into the top movers in the S&P500 index of Thursday's pre-market session.
The US market session of Thursday has yet to be opened, let's have a look at the top S&P500 gainers and losers in the pre-market session today.
Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire
Incyte (INCY) Teams Up with QIAGEN to Boost Blood Cancer Diagnostic Solutions
Incyte Corporation (NASDAQ:INCY) is one of the 10 biotech stocks screaming a buy. On June 17, Incyte was a big mover in the market, announcing the signing of a strategic partnership with Netherlands QIAGEN N.V. QGEN. The two are coming together to enhance the development of a novel diagnostic panel to support investigational treatments for […]
INCYTE CORP (NASDAQ:INCY) – A Biopharmaceutical Stock with Undervalued Potential
INCYTE CORP (NASDAQ:INCY) shows strong valuation, profitability, and financial health, making it an interesting pick for value investors. The stock trades at a discount to peers with solid growth prospects ahead.
Cisco upgraded, CoreWeave downgraded: Wall Street’s top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Deutsche Bank upgraded Cisco (CSCO) to Buy from Hold with a price target of $73, up from $65. The firm sees improved visibility towards “durable” mid-single-digit growth in upcoming years for Cisco, with tailwinds from artificial intelligence, a Campus portfolio refresh, more favorable near-term compet
Factbox-Stablecoin adoption by corporates poised to grow after US Senate passes key bill
(Reuters) -The U.S. Senate has passed a bill to create a regulatory framework for stablecoins, a once-niche corner of the crypto industry that is gaining traction among global companies. Stablecoins, a type of cryptocurrency designed to maintain a constant value – typically pegged 1:1 to the U.S. dollar – are widely used by crypto traders to move funds between tokens. The Republican-controlled House of Representatives must pass its version of the bill, known as the GENIUS Act, before it heads to President Donald Trump's desk for approval.
Cisco upgraded, CoreWeave downgraded: Wall Street's top analyst calls
Cisco upgraded, CoreWeave downgraded: Wall Street's top analyst calls
Stay updated with the S&P500 stocks that are on the move in today's pre-market session.
The US market session of Monday has yet to be opened, let's have a look at the top S&P500 gainers and losers in the pre-market session today.
Incyte's Experimental Therapy Shows Platelet Normalization And Safety In Rare Blood Cancer Trials Across Doses
Incyte's INCA033989 showed early efficacy and strong tolerability in essential thrombocythemia patients with mutCALR, supporting further development.
Why Incyte Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket
Retail Investors Flock To Incyte As Drug Data, Qiagen Deal Fuel Optimism
Stifel also upgraded the stock to ‘Buy’ with a $107 price target.
Jefferies Turns Bullish on Quaker Chemical, Sees Upside Potential
Quaker Chemical Corporation (NYSE:KWR) is one of the 8 cheap beginner stocks to buy right now. On June 9, Quaker Chemical Corporation (NYSE:KWR) was upgraded from Hold to Buy by Jefferies analysts. In keeping with its optimistic assessment of the company’s performance, the firm also increased its price target from $115 to $146. Despite challenges […]
Incyte (INCY) Targets $1B Growth by 2029 with New Drug Launches
Incyte Corporation (NASDAQ:INCY) is one of the 8 cheap beginner stocks to buy right now. At the 46th Annual Global Healthcare Conference hosted by Goldman Sachs on June 9, Incyte Corporation (NASDAQ:INCY) delivered a presentation, detailing its long-term strategic goals. The company highlighted its growing pipeline and expected revenue growth from new pharmaceutical launches while addressing […]
Gates Industrial (GTES) Gets Target Hike as Margin Expansion Confidence Grows
Gates Industrial Chemical Corporation (NYSE:GTES) is one of the 8 cheap beginner stocks to buy right now. Jeffrey Hammond, a KeyBanc analyst, raised his price target for Gates Industrial Chemical Corporation (NYSE:GTES) from $23 to $26 on June 9 while maintaining the stock’s rating of Overweight. This decision comes after meetings with investors and meetings with […]
Loop Capital Raises HPE Price Target to $18 After Strong AI Server Performance
Hewlett Packard Enterprise Company (NYSE:HPE) is one of the 8 cheap beginner stocks to buy right now. Loop Capital Markets revised its financial outlook for Hewlett Packard Enterprise Company (NYSE:HPE) on June 9, maintaining its Hold rating on the company’s shares while increasing the price target from $16 to $18. The change was made in response […]
UBS Maintains Neutral on Kroger Ahead of Earnings, Sees Balanced Risk-Reward Outlook
The Kroger Co. (NYSE:KR) is one of the 8 cheap beginner stocks to buy right now. On June 9, UBS reiterated its Neutral rating on The Kroger Co. (NYSE:KR), keeping its price target at $66. As the retailer gets closer to its first-quarter earnings release, which is set for June 20, the firm’s analysis hints at […]
Berenberg Bank Maintains a Hold Rating on Novartis (NVS)
Novartis AG (NYSE:NVS) is one of the 11 Best Drug Stocks to Buy According to Hedge Funds. On June 12, Berenberg Bank analyst Luisa Hector maintained a Hold rating on Novartis AG (NYSE:NVS) and set a price target of CHF89.00. The same day, the company reported statistically significant improvements in the Phase IIIB APPULSE-PNH study. […]
Morgan Stanley Raises Tenet Healthcare (THC) PT to $210, Keeps Overweight Rating
Tenet Healthcare Corporation (NYSE:THC) is one of the 8 Best Inexpensive Stocks to Buy Right Now. On June 9, Morgan Stanley raised its price target on Tenet Healthcare to $210 from $175, while maintaining an Overweight rating on the shares. Analyst Craig Hettenbach highlighted Tenet Healthcare as Morgan Stanley’s preferred stock within the hospital sector. […]
Truist Lowers Elevance Health (ELV) to $500, Keeps Buy Rating
Elevance Health Inc. (NYSE:ELV) is one of the 8 Best Inexpensive Stocks to Buy Right Now. On June 9, Truist analyst David MacDonald slightly reduced the firm’s price target on Elevance Health from $510 to $500, while maintaining a Buy rating on the shares. Despite the adjustment, the analyst remains positive on Elevance Health’s substantial […]
Oil ETFs Gain Renewed Attention on Israel-Iran Conflict
- As the geopolitical situation evolves, oil and energy ETFs are likely to remain in the spotlight. - Markets are on edge about the possibility of future damage to Iran’s facilities.
Specialised Therapeutics announces expanded partnership with Incyte
Specialised Therapeutics announced the expansion of its existing supply and distribution agreement with Incyte (INCY) Biosciences International Sarl, the Swiss-based affiliate of Incyte, to launch and distribute two additional medicines from its oncology portfolio in Australia, New Zealand and Singapore, with an option to add further countries in the Asia-Pacific region. The expanded agreement will see new therapies axatilimab and retifanlimab added to the current partnered portfolio of Minjuvi
Specialised Therapeutics Expands Partnership with Incyte to Include Two Additional Therapies for Hard-to-Treat Conditions
/PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce the expansion of its existing supply and...
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Qiagen (QGEN) Up 8.1% Since Last Earnings Report: Can It Continue?
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Mentions: QGEN